This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

HRA response to the European Medicines Agency Concept paper on the revision of the Guideline on strategies to identify and mitigate risks for first-in-human CTIMPs

Last updated on 3 Oct 2016

The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union (EU), has recently consulted on a concept paper on the revision of the ‘Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products’.

The concept paper sets out proposed changes to current guidance on first-in-human clinical trials to further improve strategies to identify and mitigate risks to trial participants. Our response to this consultation can be found here.

Back to news & updates